valsartan has been researched along with enalapril in 161 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (4.35) | 18.2507 |
| 2000's | 36 (22.36) | 29.6817 |
| 2010's | 92 (57.14) | 24.3611 |
| 2020's | 26 (16.15) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Angeli, P; Bodin, F; Fogari, R; Heath, R; Hereng, C; Holwerda, NJ; Oddou-Stock, P; Porcellati, C | 1 |
| Hayashi, N; Inukai, T; Kometani, M; Nakao, K; Yamamoto, S | 2 |
| Hayashi, N; Kometani, M; Nakao, K; Yamamoto, S | 1 |
| Fujimura, Y; Hayashi, N; Kometani, M; Nakao, K; Yamamoto, S | 1 |
| Brunner, HR; Burnier, M; Fricker, AF; Meilenbrock, S; Nussberger, J | 1 |
| Bertocchi, F; Cuocolo, A; Damiano, M; Iovino, GL; Izzo, R; Mann, J; Storto, G; Trimarco, B | 1 |
| Cukon, S; Ennezat, PV; Hammer, A; Infeld, J; Jorde, UP; Le Jemtel, TH; Lisker, J; Sonnenblick, EH; Suryadevara, V | 1 |
| Blanco, M; Botero, R; Del Portillo, H; María, E; Matiz, H; Orejarena, H; Velez, JR | 1 |
| Finckenberg, P; Lassila, M; Nurminen, ML; Pere, AK; Vapaatalo, H | 1 |
| Laverty, R; Ledingham, JM | 1 |
| Ahonen, J; Finckenberg, P; Krogerus, L; Lassila, M; Nurminen, ML; Pere, AK; Vapaatalo, H | 1 |
| Kolina, IB; Neverov, NI; Shilov, EM; Shvetsov, MIu; Stavrovskaia, EV; Zakharova, EV | 1 |
| De Gasparo, M; Domergue, V; Fornes, P; Giudicelli, JF; Richer, C | 1 |
| Lewis, W; Stebbins, CL; Warren, JH; Wraa, CE | 1 |
| Bruneval, P; Clozel, JP; de Gasparo, M; Hess, P; Nuesslein-Hildesheim, B | 1 |
| Rapi, J | 1 |
| Dagistanli, FK; Erek, E; Kalender, B; Oztürk, M; Tunçdemir, M; Uysal, O; Yegenaga, I | 1 |
| Borovkov, NN; Sidorova, NV | 1 |
| Gordon, A; Helmers, C; Löfdahl, P; Pantev, E; Rydberg, E; Willenheimer, R | 1 |
| Carretero, OA; Kapke, A; Liu, YH; Shesely, EG; Xu, J; Yang, F; Yang, XP | 1 |
| Nesterov, IuI; Spoeva, VI; Tepliakov, AT | 1 |
| Clozel, JP; Clozel, M; de Gasparo, M; Germann, PG; Hess, P; Persohn, E; Roman, D; Webb, RL | 1 |
| deBlois, D; Der Sarkissian, S; Duguay, D; Hamet, P; Marchand, EL | 1 |
| Akino, M; Chiba, S; Kitabatake, A; Kumamoto, H; Matsui, Y; Mikami, T; Nan, J; Okamoto, H; Onozuka, H; Shimizu, T; Sugawara, T | 1 |
| Fogari, R; Marasi, G; Mugellini, A; Pasotti, C; Poletti, L; Preti, P; Rinaldi, A; Zoppi, A | 1 |
| Komuro, I; Kuwabara, Y | 1 |
| Cimpanelli, M; Crespi, C; Gaudio, G; Grandi, AM; Guasti, L; Klersy, C; Riganti, G; Schizzarotto, A; Simoni, C; Venco, A | 1 |
| Adani, GL; Baccarani, U; Boscutti, G; Bresadola, F; Gropuzzo, M; Mioni, G; Mioni, R; Montanaro, D; Risaliti, A; Sainz, M; Tulissi, P; Vallone, C | 1 |
| Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K | 1 |
| Hatori, T; Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Hausberg, M; Hohage, H; Kosch, M | 1 |
| Coleman, CI; Kalus, JS; White, CM | 1 |
| Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F | 1 |
| Breekveldt-Postma, NS; Erkens, JA; Herings, RM; Khan, ZM; Siiskonen, SJ; Vincze, G | 1 |
| Ayala, DE; Calvo, C; Hermida, RC; Khder, Y | 1 |
| Asai, S; Ishikawa, K; Nishida, Y; Sugahara-Kobayashi, M; Takahashi, Y | 1 |
| Galle, J | 1 |
| Bozkurt, D; Cetin, P; Duman, S; Ertilav, M; Hur, E; Nar, H; Sezak, M; Sipahi, S | 1 |
| Iwasaka, T; Kawamura, A; Masue, Y; Sugiura, T; Yokoe, H; Yuasa, F | 1 |
| Furuyama, M; Hashimoto, T; Hayasaka, K; Matsunaga, A; Ogino, D; Toyoda, K | 1 |
| Chen, X; Dong, J; Jiang, L; Jiang, W; So, Y; Xin, H | 1 |
| Bengel, FM; Bravo, PE; Dannals, RF; Fukushima, K; Higuchi, T; Javadi, MS; Lautamäki, R; Mathews, WB; Szabo, Z; Xia, J | 1 |
| Chen, ZY; Huang, Y; Lau, CW; Leung, FP; Tian, XY; Wong, WT; Yao, X; Yung, LH; Yung, LM | 1 |
| Circelli, M; Cremonesi, G; Fogari, R; Mugellini, A | 1 |
| Derbentseva, EA; Dralova, OV; Ermolaeva, AS; Maksimov, ML; Starodubtsev, AK | 1 |
| Grosso, A; Kadwa, M; Litwin, M; Pezous, N; Schaefer, F; Turi, S; Zachwieja, J; Zurowska, A | 1 |
| Croxtall, JD | 1 |
| Bozcali, E; Dedeoglu, DB; Karpuz, H; Karpuz, V; Suzer, O | 1 |
| Desai, AS; Gong, J; Lefkowitz, MP; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, J; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| El-Maraghy, SA; Motawi, TK; Senousy, MA | 1 |
| Barreira, JC; Iotti, A; Laborde, HA; Rivero, MA; Zazzetti, F | 1 |
| Desai, AS; Gong, J; Lefkowitz, M; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Costa, AP; Costa, As; Junior, AS; Muratori, MC; Reis, AM; Viana, GE | 1 |
| Jessup, M | 1 |
| Desai, AS; Gong, J; Lefkowitz, MP; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Fox, KA; Jessup, M; Komajda, M; McMurray, JJ; Packer, M | 1 |
| Cheng, KK; Etemadi, A; Hemming, K; Jaafari, E; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marjani, H; Marshall, T; Merat, S; Mohammadifard, N; Naemi, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Sadeghi, M; Sarrafzadegan, N; Thomas, GN | 1 |
| Einecke, D | 2 |
| Dulsat, C | 1 |
| Andersen, K; Arango, JL; Arnold, JM; Bělohlávek, J; Böhm, M; Boytsov, S; Burgess, LJ; Cabrera, W; Calvo, C; Chen, CH; Desai, AS; Duarte, YC; Dukat, A; Erglis, A; Fu, M; Gomez, E; Gong, J; Gonzàlez-Medina, A; Hagège, AA; Huang, J; Katova, T; Kiatchoosakun, S; Kim, KS; Kozan, Ö; Lefkowitz, MP; Llamas, EB; Martinez, F; McMurray, JJ; Mendoza, I; Merkely, B; Mosterd, A; Negrusz-Kawecka, M; Packer, M; Peuhkurinen, K; Ramires, FJ; Refsgaard, J; Rizkala, AR; Rosenthal, A; Rouleau, JL; Senni, M; Shi, VC; Sibulo, AS; Silva-Cardoso, J; Solomon, SD; Squire, IB; Starling, RC; Swedberg, K; Teerlink, JR; Vanhaecke, J; Vinereanu, D; Wong, RC; Zile, M | 1 |
| Krum, H | 1 |
| Andersen, K; Arango, JL; Arnold, M; Bayram, E; Bĕlohlávek, J; Böhm, M; Boytsov, S; Burgess, L; Cabrera, W; Chen, CH; Desai, A; Erglis, A; Fu, M; Gomez, E; Gong, J; Gonzalez, A; Greenlaw, N; Hagege, AA; Katova, T; Kiatchoosakun, S; Kim, KS; Lefkowitz, M; Martinez, F; McMurray, J; Mendoza, I; Merkely, B; Mosterd, A; Negrusz-Kawecka, M; Packer, M; Peuhkurinen, K; Ramires, F; Refsgaard, J; Rizkala, A; Rouleau, J; Senni, M; Shi, V; Sibulo, AS; Silva-Cardoso, J; Solomon, S; Squire, I; Starling, RC; Swedberg, K; Teerlink, JR; Vinereanu, D; Wong, R; Zile, MR | 1 |
| Ferrari, L; Sada, S | 1 |
| McMurray, JJ | 1 |
| Widimský, J | 1 |
| Brahimi, A; Chen, F; Claggett, B; Desai, AS; Finn, PV; Gong, J; Hartley, LH; Lefkowitz, M; Liu, J; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, JL; Shi, V; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Akhter, N; Huda, S | 1 |
| Fath, R | 1 |
| Macdonald, PS | 1 |
| Jacob, MS; Sabe, MA; Taylor, DO | 1 |
| Desai, AS; Gong, J; Jhund, PS; Lefkowitz, MP; Martinez, F; McMurray, JJV; Mosterd, A; Packer, M; Ramires, F; Rizkala, AR; Rouleau, JL; Senni, M; Shi, VC; Silva Cardoso, J; Simpson, J; Solomon, SD; Squire, I; Swedberg, K; Zile, MR | 1 |
| Cao, YM; Gao, WH; Hu, JW; Lv, YB; Mu, JJ; Wang, Y; Xie, BQ; Yan, DY; Yuan, ZY; Zheng, WL | 1 |
| Cardoso, JS; Desai, AS; Jhund, PS; Kristensen, SL; Lefkowitz, MP; Martinez, F; McMurray, JJ; Merkely, B; Packer, M; Preiss, D; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Squire, I; Starling, RC; Swedberg, K; Zile, MR | 1 |
| Correia, LC; Rassi, A | 1 |
| Claggett, B; Desai, AS; Dukat, A; Kozan, Ö; Lefkowitz, MP; McMurray, JJ; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Starling, RC; Swedberg, K; Zile, M | 1 |
| Feng, S; Guo, Z; Han, P; Li, J; Ma, Y; Zhao, X | 1 |
| Brown, NJ; Hubers, SA | 1 |
| Coats, AJ; Lainscak, M | 1 |
| Bellows, BK; Bress, AP; King, JB; Nelson, RE; Shah, RU | 1 |
| Gong, J; Jhund, PS; Lefkowitz, MP; McMurray, JJ; Okumura, N; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 2 |
| Vilela-Martin, JF | 1 |
| Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Teerlink, JR; Vardeny, O; Zile, MR | 1 |
| Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, J; Shi, V; Solomon, S; Swedberg, K; Zile, M | 1 |
| Claggett, B; Desai, A; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Chan, WW; Claggett, B; Deschaseaux-Voinet, C; Fonarow, GC; Gaziano, TA; McMurray, JJ; Rouleau, JL; Solomon, SD; Turner, SJ; Zile, MR | 1 |
| Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, JL; Shi, V; Solomon, SD; Swedberg, K; Vardeny, O; Zile, MR | 1 |
| Ezekowitz, JA | 1 |
| Cannon, JA; Chen, F; Gong, J; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJ; Packer, M; Rouleau, JL; Shen, L; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Huynh, K | 1 |
| Claggett, BL; Desai, AS; Gong, J; McMurray, JJ; Packer, M; Prescott, MF; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Teerlink, JR; Tyler, JM | 1 |
| Böhm, M; Gong, J; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Young, R; Zile, MR | 1 |
| Kobalava, ZD; Lukina, OI; Villevalde, SV | 1 |
| Holcman, K; Kostkiewicz, M; Leśniak-Sobelga, A; Podolec, P; Rubiś, P; Wiśniowska-Śmiałek, S | 1 |
| Fernández-Ruiz, I | 1 |
| Guo, J; Wong, PC; Zhang, A | 1 |
| McCartney, M | 1 |
| Gong, J; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJV; Mogensen, UM; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Claggett, BL; Desai, AS; Lefkowitz, MP; Lewis, EF; Liu, J; McMurray, JJV; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Bleske, BE; Rida, N; Shi, J; Wang, X; Wu, AH; Zhu, HJ | 1 |
| Aziz, MIA; Bin-Chia Wu, D; Leong, KTG; Liang, L; Ng, K; Sim, D; Tan, D; Wei, YQ; Wong, R | 2 |
| Bonnet, D; Burch, M; Bush, C; Canter, C; Chen, F; Halnon, N; Kantor, P; Kochilas, L; Rossano, J; Shaddy, R; Zhao, Z | 1 |
| Ademi, Z; Deschaseaux, C; Hancock, E; Haroun, RH; Pfeil, AM; Schwenkglenks, M; Trueman, D | 1 |
| de Boer, RA; Koenders, JMA; Linssen, GCM; Meeder, JG; Ramos, IC; Rutten-van Mölken, MPMH; Versteegh, MM | 1 |
| Aldemerdash, A; Berei, TJ; Hollis, IB; Hsu, CC; Rodgers, JE; Smith, KR; Vardeny, O | 1 |
| Claggett, BL; Desai, AS; Gong, J; Jhund, PS; Køber, L; Lefkowitz, MP; McMurray, JJV; Mogensen, UM; Mueller-Velten, G; Packer, M; Rouleau, JL; Shen, L; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Chandra, A; Claggett, BL; Desai, AS; Katova, T; Lefkowitz, MP; Lewis, EF; McMurray, JJV; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; Hernandez, AF; McCague, K; Morrow, DA; Rocha, RA; Velazquez, EJ | 1 |
| Chiang, LM; Claggett, B; McMurray, JJV; O'Meara, E; Packer, M; Prescott, MF; Rouleau, JL; Solomon, SD; Zile, MR | 1 |
| Kaplan, A; Modgill, V; Senni, M; Shi, V; Streefkerk, H; Zhou, W | 1 |
| Krittayaphong, R; Permsuwan, U | 2 |
| Ghafar, MZ; Mulkerrin, EC; O'Keeffe, ST; Sharkey, AT | 1 |
| Cristino, J; Lee, D; Ng, C; Tan, J; Tang, I; Trueman, D | 1 |
| Gandjour, A; Ostwald, DA | 1 |
| Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| Claggett, BL; Desai, AS; Fonarow, GC; McMurray, JJV; Packer, M; Rouleau, JL; Solomon, SD; Srivastava, PK; Swedberg, K; Zile, MR | 1 |
| Ter Maaten, JM | 1 |
| Claggett, B; Desai, AS; Kachadourian, J; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Vardeny, O; Zile, MR | 1 |
| Claggett, B; Lefkowitz, M; McMurray, JJV; O'Meara, E; Packer, M; Prescott, MF; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Fonarow, GC; Srivastava, PK | 1 |
| Ambrosy, AP; Braunwald, E; Desai, AS; DeVore, AD; Duffy, CI; Gurmu, Y; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| Balmforth, C; Jhund, PS; Lefkowitz, M; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shen, L; Shi, V; Simpson, J; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Braunwald, E; DeVore, AD; Duffy, CI; Gurmu, Y; McCague, K; Morrow, DA; Prescott, MF; Rocha, R; Velazquez, EJ | 1 |
| Packer, M | 1 |
| Boffetta, P; Brennan, P; Cheng, KK; Etemadi, A; Fazel, A; Gharavi, A; Hemming, K; Kamangar, F; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marshall, T; Merat, S; Mohammadifard, N; Naemi-Tabiei, M; Nalini, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Roshandel, G; Sadeghi, M; Sarrafzadegan, N; Thomas, N | 1 |
| Meyer, P; Reny, JL; Russo-Vorms, L | 1 |
| Książczyk, M; Lelonek, M | 1 |
| Ambrosy, AP; Braunwald, E; Chakraborty, H; DeVore, AD; Duffy, CI; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| Comin-Colet, J; Ecochard, L; Edelmann, F; Hussain, RI; Jaarsma, T; Piepoli, MF; Schorr, J | 1 |
| Ambrosy, AP; Chioncel, O | 1 |
| Fu, X; Wang, H | 1 |
| Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; McCague, K; Meng, X; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| Akoz Saydam, F; Bozkurt, M; Caglar, A; Kurt, M; Serin, M | 1 |
| Ambrosy, AP; Berardi, C; Braunwald, E; Chakraborty, H; DeVore, AD; Duffy, CI; Morrow, DA; Mulder, HS; O'Brien, TX; Velazquez, EJ | 1 |
| Birkeland, K; Fombu, E; Grant, D; Heywood, JT; Khandwalla, RM; Owens, RL; Steinhubl, SR | 1 |
| Comin-Colet, J; Dosantos, R; Edelmann, F; Ferber, P; Hussain, RI; Jaarsma, T; Piepoli, MF | 1 |
| Desai, AS; Guo, W; Iimori, T; Ito, H; Kitamura, T; Momomura, SI; Ohishi, T; Saito, Y; Sakata, Y; Tsutsui, H; Yamamoto, K | 1 |
| Bhatt, AS; Claggett, BL; Desai, AS; Lefkowitz, MP; Liu, J; McMurray, JJV; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Vaduganathan, M; Vardeny, O; Zile, MR | 1 |
| Briasoulis, A; Kuno, T; Ueyama, H | 1 |
| Chun, KH; Ha, J; Kang, SM; Kim, H; Lee, CJ; Lee, S; Lee, SH; Oh, J; Park, S; Yoon, M | 1 |
| Ademi, Z; Liew, D; Perera, K; Zomer, E | 1 |
| Birkeland, K; Dorn, J; Fombu, E; Grant, D; Heywood, JT; Khandwalla, R; Owens, RL; Steinhubl, SR | 1 |
| Chen, Z; Deng, Q; Diao, K; He, S; He, Y; Huang, B; Li, C; Ma, M; Sun, J; Tang, L; Wang, D; Wang, H; Wang, M; Wu, T; Wu, X; Yan, T; Zhang, L; Zhu, Y | 1 |
| Liu, H; Liu, X; Wang, L; Xu, Q; Zhang, L | 1 |
| Claggett, B; Desai, AS; Fang, JC; Januzzi, JL; Mitchell, GF; Murphy, SP; Myhre, PL; Prescott, MF; Solomon, SD; Ward, JH | 1 |
| Claggett, B; Cunningham, JW; Jackson, A; Lefkowitz, M; McMurray, JJV; Packer, M; Pfeffer, MA; Rouleau, J; Rørth, R; Shah, SJ; Solomon, SD; Swedberg, K; Vaduganathan, M; Wijkman, MO; Zile, M | 1 |
| Xu, Z; Yang, S; Zhang, X | 1 |
| Babes, EE; Behl, T; Bungau, SG; Horvath, T; Iovanovici, DC; Moisi, M; Rus, M; Tit, DM; Vesa, CM | 1 |
| Alacapa, J; Alconera, CJ; Almirol, BJ; Caesar Delos Trinos, JP; Gerodias, F; Leong, RN; Lim, S; Mojica, VJ; Paredes, KP; Tamayo, RL; Tumanan-Mendoza, B | 1 |
| Adamson, C; Curtain, JP; Desai, AS; Docherty, KF; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Tchernev, G | 1 |
21 review(s) available for valsartan and enalapril
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Irbesartan: a new possibility in the treatment of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Controlled Clinical Trials as Topic; Drug Administration Schedule; Enalapril; Half-Life; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2002 |
[Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Enalapril; Heart Failure; Humans; Indoles; Lisinopril; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2005 |
The impact of suppressing the renin-angiotensin system on atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Combined Modality Therapy; Electric Countershock; Enalapril; Humans; Indoles; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2006 |
Reduction of proteinuria with angiotensin receptor blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biomarkers; Cardiovascular Diseases; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Indans; Irbesartan; Losartan; Nitrobenzenes; Obesity; Olmesartan Medoxomil; Piperazines; Ramipril; Tetrazoles; Valine; Valsartan | 2011 |
Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2015 |
[The new drug is much more effective than ACE inhibitors in chronic heart failure].
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure, Systolic; Hospitalization; Humans; Male; Middle Aged; Tetrazoles; Valsartan | 2015 |
Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Neprilysin; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; Valsartan | 2015 |
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Topics: Abnormalities, Drug-Induced; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Bradykinin; Contraindications; Drug Combinations; Drug Costs; Drug Synergism; Enalapril; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Failure; Humans; Hyperkalemia; Hypertension; Kidney; Multicenter Studies as Topic; Natriuretic Peptides; Neprilysin; Pregnancy; Prodrugs; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Thiazepines; Valsartan | 2016 |
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2016 |
The safety of sacubitril-valsartan for the treatment of chronic heart failure.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Chronic Disease; Drug Combinations; Enalapril; Heart Failure; Humans; Risk Factors; Tetrazoles; Valsartan | 2017 |
[A Breakthrough in the Treatment of Patients With Heart Failure With Reduced Ejection Fraction: the Clinical Significance of the PARADIGM HF-Trial].
Topics: Angiotensin Receptor Antagonists; Clinical Trials as Topic; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2017 |
PARADIGM-HF Trial: Secondary Analyses Address Unanswered Questions.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Humans; Prospective Studies; Tetrazoles; Valsartan | 2018 |
[« ARNI » (Angiotensin Receptor-Neprilysin Inhibitor): when, for whom and how?]
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Cognition; Drug Combinations; Enalapril; Heart Failure; Humans; Kidney; Neprilysin; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Enalapril; Enzyme Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Neprilysin; Ramipril; Severity of Illness Index; Stroke Volume; Valsartan; Ventricular Dysfunction, Left | 2021 |
Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminobutyrates; Atrial Fibrillation; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Randomized Controlled Trials as Topic; Valsartan | 2022 |
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diuretics; Drug Combinations; Enalapril; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents | 2022 |
Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Prospective Studies; Quality of Life; Renin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
63 trial(s) available for valsartan and enalapril
| Article | Year |
|---|---|
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.
Topics: Adult; Age Factors; Aged; Angiotensin II; Antihypertensive Agents; Double-Blind Method; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1996 |
Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Enalapril; Humans; Indomethacin; Kidney; Male; Natriuresis; Reference Values; Renal Circulation; Single-Blind Method; Tetrazoles; Valine; Valsartan | 1998 |
Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril.
Topics: Adult; Angiography; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Double-Blind Method; Enalapril; Exercise Test; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Radionuclide Imaging; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1999 |
Efficacy and safety of valsartan compared with enalapril at different altitudes.
Topics: Adult; Altitude; Antihypertensive Agents; Colombia; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Safety; Tetrazoles; Valine; Valsartan | 2000 |
Central and peripheral effects of angiotensin II on the cardiovascular response to exercise.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Blood Pressure; Enalapril; Epinephrine; Exercise; Female; Heart Rate; Humans; Male; Norepinephrine; Receptor, Angiotensin, Type 1; Stroke Volume; Tetrazoles; Valine; Valsartan; Vascular Resistance | 2001 |
Safety and efficacy of valsartan versus enalapril in heart failure patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
[Efficacy and tolerance of ACE inhibitor invoril and angiotensin I At-receptor blocker diovan in patients with stages I-II of arterial hypertension].
Topics: Adult; Aged; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Drug Tolerance; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2002 |
Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cognition; Enalapril; Female; Humans; Hypertension; Male; Memory; Tetrazoles; Valine; Valsartan | 2004 |
Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Creatinine; Enalapril; Follow-Up Studies; Humans; Hypertension; Kidney Function Tests; Kidney Transplantation; Losartan; Proteinuria; Ramipril; Renal Artery; Renin-Angiotensin System; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Heart; Heart Failure; Humans; Male; Mediastinum; Middle Aged; Natriuretic Peptide, Brain; Observer Variation; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan | 2006 |
Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol; Enalapril; Female; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Prospective Studies; Severity of Illness Index; Tetrazoles; Uric Acid; Valine; Valsartan | 2008 |
Augmented sympathoinhibitory effect of valsartan when added to angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteries; Baroreflex; Drug Synergism; Enalapril; Female; Heart; Hemodynamics; Humans; Lung; Male; Middle Aged; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Drug-Related Side Effects and Adverse Reactions; Enalapril; Female; Humans; Hypertension; Male; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure, Systolic; Hospitalization; Humans; Morbidity; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Single-Blind Method; Survival Rate; Tetrazoles; Valsartan | 2013 |
Inhibition of angiotensin-converting enzyme increases oestradiol production in ewes submitted to oestrous synchronization protocol.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Enalapril; Estradiol; Estrus Synchronization; Female; Sheep; Tetrazoles; Valine; Valsartan | 2014 |
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2014 |
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Protocols; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Polypharmacy; Primary Prevention; Research Design; Secondary Prevention; Sodium Chloride Symporter Inhibitors; Time Factors; Treatment Outcome; Valsartan | 2015 |
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Valsartan | 2015 |
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Placebo Effect; Tetrazoles; Treatment Outcome; Valsartan | 2015 |
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Tetrazoles; Treatment Outcome; Valsartan | 2015 |
A new class of drugs for systolic heart failure: The PARADIGM-HF study.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Cough; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure, Systolic; Hospitalization; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Neprilysin; Renal Insufficiency; Tetrazoles; Valsartan | 2015 |
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Global Health; Heart Failure; Humans; Male; Middle Aged; Morbidity; Neprilysin; Prognosis; Prospective Studies; Risk Assessment; Survival Rate; Tetrazoles; Valsartan; Young Adult | 2015 |
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Blood Glucose; Comorbidity; Diabetes Mellitus; Disease-Free Survival; Drug Combinations; Enalapril; Female; Glycated Hemoglobin; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prediabetic State; Prevalence; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Single-Blind Method; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Proportional Hazards Models; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
Topics: Aged; Ambulatory Care; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Endpoint Determination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Protease Inhibitors; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2016 |
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2016 |
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Chi-Square Distribution; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Kidney; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Dropouts; Proportional Hazards Models; Prospective Studies; Risk Factors; Severity of Illness Index; Single-Blind Method; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2016 |
Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Case-Control Studies; Disease Progression; Double-Blind Method; Drug Combinations; Drug Substitution; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiotonic Agents; Defibrillators, Implantable; Diuretics; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Electric Countershock; Enalapril; Heart Failure; Humans; Myocardial Revascularization; Proportional Hazards Models; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2016 |
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Hyperkalemia; Incidence; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Amnesia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Confusion; Delirium; Dementia; Disorders of Excessive Somnolence; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Proportional Hazards Models; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Prospective Studies; Single-Blind Method; Stroke Volume; Treatment Outcome; Valsartan | 2016 |
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Chronic Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Global Health; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Revascularization; Prospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Valsartan | 2017 |
Health-Related Quality of Life Outcomes in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Follow-Up Studies; Health Status; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2017 |
Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
Topics: Adolescent; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Infant; Infant, Newborn; Male; Myocardial Ischemia; Prospective Studies; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Stroke Volume; Switzerland; Tetrazoles; Valsartan | 2017 |
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Enalapril; Europe; Female; Heart Failure; Humans; Male; Middle Aged; Morbidity; Prospective Studies; Recurrence; Stroke Volume; Survival Rate; Tetrazoles; United States; Valsartan | 2018 |
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
Topics: Activities of Daily Living; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Exercise; Female; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Social Behavior; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
Topics: Administration, Oral; Aged; Aminobutyrates; Biphenyl Compounds; Cardiac Output, Low; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Safety; Peptide Fragments; Prognosis; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Allergic Agents; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Assessment; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Output, Low; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Dat
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Double-Blind Method; Drug Combinations; Enalapril; Female; Follow-Up Studies; Heart Arrest; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Prognosis; Prospective Studies; Quebec; Stroke Volume; Survival Rate; Sweden; Tetrazoles; Time Factors; United Kingdom; United States; Valsartan | 2018 |
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biological Availability; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Enalapril; Female; Furosemide; Heart Failure; Humans; Male; Medication Therapy Management; Middle Aged; Outcome Assessment, Health Care; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Cohort Studies; Drug Combinations; Enalapril; Extracellular Matrix; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2019 |
In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Hospital Mortality; Hospitalization; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.
Topics: Aminobutyrates; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Risk; Survival Analysis; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiomyopathy, Alcoholic; Cardiomyopathy, Dilated; Cardiotoxicity; Cardiovascular Diseases; Cause of Death; Dangerous Behavior; Diabetic Cardiomyopathies; Drug Combinations; Enalapril; Female; Heart Failure; Heart Valve Diseases; Hospitalization; Humans; Hypertension; Infections; Male; Middle Aged; Mortality; Myocardial Ischemia; Peripartum Period; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Virus Diseases | 2019 |
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Cyclic GMP; Drug Combinations; Enalapril; Female; Heart Failure; Hemodynamics; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Tetrazoles; Treatment Outcome; Troponin; Valsartan | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Valsartan | 2019 |
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Discharge; Peptide Fragments; Tetrazoles; Valsartan | 2020 |
Rationale and study design of OUTSTEP-HF: a randomised controlled study to assess the effect of sacubitril/valsartan and enalapril on physical activity measured by accelerometry in patients with heart failure with reduced ejection fraction.
Topics: Accelerometry; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Europe; Exercise; Heart Failure; Humans; Quality of Life; Stroke Volume; Valsartan | 2020 |
Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Anterior Wall Myocardial Infarction; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Echocardiography; Enalapril; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2021 |
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Death; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valsartan | 2020 |
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Black or African American; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Valsartan | 2020 |
The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure.
Topics: Actigraphy; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Comorbidity; Double-Blind Method; Drug Combinations; Enalapril; Exercise; Female; Heart Failure; Humans; Male; Middle Aged; Severity of Illness Index; Sleep; Stroke Volume; Valsartan | 2021 |
OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Exercise; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Japan; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Sleep Outcomes From AWAKE-HF: A Randomized Clinical Trial of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Sleep; Stroke Volume; Tetrazoles; Valsartan; Wakefulness | 2021 |
Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Prospective Studies; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Remodeling | 2021 |
The Relationship between Angiotensin-Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure.
Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Echocardiography; Enalapril; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
77 other study(ies) available for valsartan and enalapril
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Dogs; Enalapril; Heart Rate; Hypertension; Hypertension, Renal; Male; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Tetrazoles; Valine; Valsartan | 1997 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Cardiomegaly; Cerebrovascular Disorders; Enalapril; Heart Rate; Hypertension; Male; Mesentery; Muscle Contraction; Organ Size; Rats; Rats, Inbred SHR; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 1997 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Circulation; Blood Pressure; Bradykinin; Cardiac Output; Dogs; Enalapril; Female; Heart Rate; Hemodynamics; Male; Rats; Rats, Inbred SHR; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renal Circulation; Tetrazoles; Valine; Valsartan; Vascular Resistance | 1997 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Enalapril; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Organ Size; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1997 |
Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Fosinopril; Heart Failure; Humans; Lisinopril; Male; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Treatment Failure; Valine; Valsartan | 2000 |
Enalapril and valsartan improve cyclosporine A-induced vascular dysfunction in spontaneously hypertensive rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cyclosporine; Dose-Response Relationship, Drug; Enalapril; Hypertension; Male; Mesenteric Arteries; Nitroprusside; Norepinephrine; Rats; Rats, Inbred SHR; Renal Artery; Systole; Tetrazoles; Valine; Valsartan; Vasoconstriction; Vasodilation | 2000 |
Basilar artery remodelling in the genetically hypertensive rat: effects of nitric oxide synthase inhibition and treatment with valsartan and enalapril.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Basilar Artery; Blood Pressure; Brain; Enalapril; Enzyme Inhibitors; Hypertension; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Rats; Rats, Inbred SHR; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2000 |
Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykinin; Bradykinin Receptor Antagonists; Cyclosporine; Dose-Response Relationship, Drug; Drinking; Eating; Electrolytes; Enalapril; Heart Rate; Hypertension; Hypertrophy, Left Ventricular; Kallikreins; Kidney; Kidney Diseases; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Renin; Sodium, Dietary; Tetrazoles; Urination; Valine; Valsartan | 2000 |
[Effects of pathogenetic therapy on blood cholesterol in patients with glomerulonephritis].
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anticholesteremic Agents; Antihypertensive Agents; Azathioprine; Captopril; Cholesterol; Creatinine; Cyclophosphamide; Data Interpretation, Statistical; Enalapril; Female; Glomerulonephritis; Humans; Immunosuppressive Agents; Lovastatin; Male; Nephrotic Syndrome; Prednisolone; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |
Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapril; Heart Failure; Male; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2001 |
Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Drug Combinations; Enalapril; Endothelium, Vascular; Hypertension; Male; Rats; Rats, Inbred SHR; Survival Analysis; Tetrazoles; Valine; Valsartan | 2000 |
Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Female; Immunoenzyme Techniques; Immunohistochemistry; Kidney; Organ Size; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2002 |
[24-hour arterial hypertension profile and heart rhythm variability in patients with arterial hypertension and NIDDM].
Topics: Angiotensin-Converting Enzyme Inhibitors; Circadian Rhythm; Diabetes Mellitus, Type 2; Enalapril; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2002 |
Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiotonic Agents; Collagen; Enalapril; Heart Rate; Hemodynamics; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Survival Analysis; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2002 |
Combination of low-dose valsartan and enalapril improves endothelial dysfunction and coronary reserve in Nomega-nitro-L-arginine methyl ester-treated spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Coronary Circulation; Drug Therapy, Combination; Enalapril; Endothelium, Vascular; Enzyme Inhibitors; Kidney; Male; NG-Nitroarginine Methyl Ester; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2002 |
Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Apoptosis; Enalapril; Fibroblasts; Heart Ventricles; Hyperplasia; Hypertension; Hypertrophy, Left Ventricular; In Situ Nick-End Labeling; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2003 |
VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Cricetinae; Enalapril; Endothelial Growth Factors; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Neovascularization, Pathologic; Receptor, Angiotensin, Type 1; RNA, Messenger; Tetrazoles; Time Factors; Valine; Valsartan; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Changes in plasma lipids during renin-angiotensin system blockade by combination therapy (enalapril plus valsartan) in patients with diabetes and hypertension.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enalapril; Humans; Hypertension; Lipids; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2005 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan | 2005 |
[Hypertension and diabetic nephropathy, a dangerous duo].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Hypertension; Male; Metabolic Syndrome; Ramipril; Tetrazoles; Valine; Valsartan | 2005 |
Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Enalapril; Female; Glycation End Products, Advanced; Mice; Mice, Inbred C57BL; Mice, Obese; Pyridoxamine; Tetrazoles; Valine; Valsartan; Vitamin B Complex | 2006 |
Higher persistence with valsartan compared with enalapril in daily practice.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Drug Prescriptions; Enalapril; Female; Humans; Hypertension; Male; Medicine; Middle Aged; Multivariate Analysis; Netherlands; Registries; Sex Factors; Specialization; Tetrazoles; Valine; Valsartan | 2007 |
Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Brain Stem; Calcium Channel Blockers; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Enalapril; Hypertension; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Stroke; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Chlorhexidine; Disease Models, Animal; Enalapril; Female; Peritoneal Dialysis; Peritoneum; Rats; Rats, Wistar; Sclerosis; Tetrazoles; Valine; Valsartan | 2008 |
Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Apolipoproteins E; Bezafibrate; Child; Child, Preschool; Enalapril; Female; Hematuria; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Failure, Chronic; Kidney Glomerulus; Nephrotic Syndrome; Probucol; Tetrazoles; Valine; Valsartan | 2009 |
[Intermedin (IMD) gene expression in hypertrophic cardiac myocyte of renal vascular hypertension rats and the intervention of Valsartan, Amlodipine and Enalapril in the expression].
Topics: Adrenomedullin; Amlodipine; Animals; Antihypertensive Agents; Cardiomegaly; Enalapril; Hypertension, Renovascular; Male; Myocardium; Neuropeptides; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2009 |
Radionuclide imaging of angiotensin II type 1 receptor upregulation after myocardial ischemia-reperfusion injury.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Autoradiography; Enalapril; Feasibility Studies; Male; Myocardial Reperfusion Injury; Myocardium; Positron-Emission Tomography; Pyridines; Radiopharmaceuticals; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Tissue Distribution; Valine; Valsartan | 2010 |
Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats.
Topics: Acetylcholine; Angiotensin II; Animals; Enalapril; Endothelium, Vascular; Estrogens; Female; Free Radical Scavengers; NADPH Oxidases; Nitric Oxide; Ovariectomy; Oxidative Stress; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Vasodilation | 2011 |
[Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].
Topics: Aged; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Drug Therapy, Combination; Enalapril; Female; Fumarates; Humans; Hypertension; Indapamide; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |
Valsartan: in children and adolescents with hypertension.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Enalapril; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2012 |
Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia/reperfusion injury as well as doxorubicin cardiotoxicity.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Doxorubicin; Enalapril; Heart Diseases; Hemodynamics; Humans; Male; Rats; Rats, Wistar; Reperfusion Injury; Tetrazoles; Valine; Valsartan | 2012 |
Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Gene Expression Regulation, Enzymologic; Kidney; Male; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2013 |
Scleroderma renal crisis in an elderly patient with overlap syndrome.
Topics: Aged; Biopsy; Enalapril; Female; Humans; Hypertension; Kidney; Renal Dialysis; Renal Insufficiency; Scleroderma, Systemic; Sjogren's Syndrome; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
Topics: Adrenergic beta-Antagonists; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diuretics; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Patient Selection; Platelet Aggregation Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2014 |
Neprilysin inhibition--a novel therapy for heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Neprilysin; Tetrazoles; Valsartan | 2014 |
PARADIGM-HF--the experts' discussion.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2014 |
[Systolic heart failure. New drug improves prognosis significantly].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Early Termination of Clinical Trials; Enalapril; Heart Failure, Systolic; Humans; Prognosis; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2014 |
A report from the European Society of Cardiology Congress 2014 (August 30-September 3 - Barcelona, Spain).
Topics: Aminobutyrates; Benzaldehydes; Benzazepines; Biphenyl Compounds; Cardiology; Cardiovascular Diseases; Drug Combinations; Enalapril; Humans; Ivabradine; Oximes; Stents; Tetrazoles; Valsartan | 2014 |
Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Disease Progression; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2015 |
Efficacy of angiotensin-neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Heart Failure; Hospitalization; Humans; Neprilysin; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan | 2015 |
Modulation of oxidative stress by enalapril and valsartan in adrenaline treated rats: a comparative study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Enalapril; Epinephrine; Female; Male; Oxidative Stress; Rats; Rats, Long-Evans; Tetrazoles; Valine; Valsartan | 2014 |
[Still trivialized too often].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; Enalapril; Germany; Heart Failure; Humans; Tetrazoles; Valsartan | 2015 |
Effects of Renin-Angiotensin System Inhibitors on Renal Expression of Renalase in Sprague-Dawley Rats Fed With High Salt Diet.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Diet; Enalapril; Hydralazine; Kidney; Male; Monoamine Oxidase; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Sodium Chloride, Dietary; Valsartan | 2015 |
Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2016 |
[Simultaneous determination of four drugs for kidney diseases in urine by high performance liquid chromatography].
Topics: Chromatography, High Pressure Liquid; Enalapril; Furosemide; Humans; Kidney Diseases; Triamterene; Valsartan | 2015 |
The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Markov Chains; Middle Aged; Neprilysin; Quality-Adjusted Life Years; Stroke Volume; Tetrazoles; Valsartan | 2016 |
[New therapy option ARNI].
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure, Systolic; Humans; Stroke Volume; Tetrazoles; Valsartan | 2016 |
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Stroke Volume; Tetrazoles; Valsartan | 2016 |
Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan | 2017 |
Heart failure: Neprilysin inhibition attenuates risk of hyperkalaemia in HFrEF.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Neprilysin; Tetrazoles; Valsartan | 2017 |
Angiotensin receptor neprilysin inhibitor treatment is safe and potentially efficacious in end‑stage hypertrophic cardiomyopathy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiomyopathy, Hypertrophic; Drug Combinations; Enalapril; Humans; Neprilysin; Patient Safety; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Diabetes: Sacubitril/valsartan improves glycaemic control.
Topics: Aminobutyrates; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Enalapril; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
The renal and cardiovascular effects of natriuretic peptides.
Topics: Aminobutyrates; Atrial Natriuretic Factor; Biphenyl Compounds; Disease Progression; Drug Combinations; Enalapril; Heart Failure; Humans; Kidney; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Natriuretic Peptides; Tetrazoles; Valsartan | 2017 |
Margaret McCartney: Only data can say if new is better.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Approval; Enalapril; Equivalence Trials as Topic; Heart Failure; Humans; United Kingdom; Valsartan | 2017 |
A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms.
Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Carboxylic Ester Hydrolases; Cell Line; Clopidogrel; Drug Combinations; Enalapril; Female; Gene Frequency; Genetic Variation; Haplotypes; Humans; Liver; Loss of Function Mutation; Male; Middle Aged; Polymorphism, Single Nucleotide; RNA, Messenger; Sequence Analysis, DNA; Tetrazoles; Ticlopidine; Valsartan; Young Adult | 2017 |
Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Markov Chains; Multivariate Analysis; Quality-Adjusted Life Years; Severity of Illness Index; Singapore; Stroke Volume; Survival Analysis; Tetrazoles; Valsartan | 2018 |
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeco
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Economics, Pharmaceutical; Enalapril; Female; Guidelines as Topic; Heart Failure; Humans; Male; Middle Aged; Models, Economic; Neprilysin; Netherlands; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2018 |
Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Needs Assessment; Outcome and Process Assessment, Health Care; Quality-Adjusted Life Years; Stroke Volume; Survival Analysis; Tetrazoles; Thailand; Valsartan; Ventricular Dysfunction, Left | 2018 |
Angiotensin receptor neprilysin inhibitors in older patients with heart failure.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2019 |
RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Budgets; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2018 |
Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Unravelling the effect of sacubitril/valsartan on loop diuretic dosing.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Tetrazoles; Valsartan | 2019 |
Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin-angiotensin system in chronic heart failure? The culmination of a 20-year journey.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valsartan | 2019 |
Improving physical activity and exercise capacity in heart failure. Taking the first step is always the hardest.
Topics: Accelerometry; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Exercise; Exercise Tolerance; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
The effects of valsartan on scar maturation in an experimental rabbit ear wound model.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cicatrix, Hypertrophic; Collagen; Ear; Enalapril; Fibroblasts; Male; Models, Animal; Rabbits; Valsartan; Wound Healing | 2020 |
Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis.
Topics: Australia; Clinical Trials as Topic; Cost-Benefit Analysis; Enalapril; Heart Failure; Humans; Valsartan | 2021 |
Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Thailand; Valsartan | 2021 |
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus; Enalapril; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemia; Insulins; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Budget Impact Analysis of Utilization of Sacubitril/Valsartan for the Treatment of Heart Failure With Reduced Ejection Fraction in the Philippines.
Topics: Aminobutyrates; Biphenyl Compounds; Enalapril; Heart Failure; Humans; Philippines; Stroke Volume; Tetrazoles; Valsartan | 2023 |
NITROSOGENESIS OF SKIN CANCER: THE NITROSAMINE CONTAMINATION IN THE CALCIUM CHANNEL BLOCKERS (AMLODIPINE), BETA BLOCKERS (BISOPROLOL), SARTANS (VALSARTAN/LOSARTAN), ACE INHIBITORS (PERINDOPRIL/ENALAPRIL), TRICYCLIC ANTIDEPRESSANTS (MELITRACEN), SSRIS (PAR
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidepressive Agents, Tricyclic; Bisoprolol; Calcium Channel Blockers; Enalapril; Humans; Incidence; Losartan; Metformin; Paroxetine; Perindopril; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Skin Neoplasms; Valsartan; Venlafaxine Hydrochloride | 2023 |